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1078–5Objectives. To compare the diagnostic and therapeutic confidence, patient outcome and costs between MRA and DSA as
the initial diagnostic imaging test, in patients with symptomatic arterial disease of the leg.
Design. Randomised controlled diagnostic trial.
Materials and methods. Patients were randomly allocated to MRA (n¼ 97) or DSA (n¼ 100). Primary outcomes were:
ability to make treatment plan and patients satisfaction. Secondary endpoints were: type of treatment and costs.
Results. A treatment plan was determined for each included patient. Additional imaging was necessary in 11% of patients
in the MRA group compared to 10% in the DSA group (p¼ 0.5). 84% of the patients who received MRA judged the
diagnostic work up as comfortable compared to 57% who had DSA (p¼ 0.013). Within 4 months of randomization 30
patients in the MRA group compared to 34 patients in de DSA group underwent operative procedures; 39 versus 36 pa-
tients respectively underwent angioplasty. The mean total in-hospital costs during the first 4 months were V4768,- in the
MRA group compared to V4697,- in the DSA group (95% CI of difference 1331;1472).
Conclusions. In patients with peripheral arterial disease of the leg an adequate treatment plan can be made with MRA.
This diagnostic strategy was experienced as more comfortable and less painful compared to DSA. Total diagnostic and
treatment costs of both strategies were comparable.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
Keywords: Magnetic resonance angiography; Digital subtraction angiography; Peripheral vascular diseases; Treatment
costs; Patient satisfaction.Introduction
For invasive treatment planning in patients with pe-
ripheral arterial disease, visualisation of the vascular
tree is necessary. The reference standard is digital sub-
traction angiography (DSA). As first line investigation
duplex scanning (DUS) can be performed. However,
DUS is time consuming and investigator dependent.
The drawbacks of DSA are a compulsory admission,
as well as risk of complications like contrast allergy or
renal toxicity. CTAorMRAare less invasive alternatives
and both have been evaluated in diagnostic research.sponding author. Dr. A. C. Vahl, MD, PhD, MSc, Dept. of
y, P.O. Box 95500, 1090 HM Amsterdam, The Netherlands.
address: a.c.vahl@olvg.nl
884/000514+ 08 $34.00/0  2007 European Society for VasculaContrast enhanced MRA (CE MRA) has been proven
a reliable techniquewith an adequate diagnostic perfor-
mance to replace DSA, described in individual studies
as well in meta-analysis.1e6 Drawbacks of MRA are
less optimal imaging of distal arteries7,8or overestima-
tionof stenoses.9Onegroupwasable todetectmorepat-
ent distal arteries.10 To avoid venous over projection of
the crural vessels in order to visualize more patent
arteries, the scanning protocol had been changed per-
forming the imaging from distal to proximal.11
MRA proved to be a reliable method for making
a treatment plan.12,13 However, in published series
as well as in our own experience, 7 to 10% of the
patients need additional diagnostic work up after
MRA.12 All previous studies have to be classified
as diagnostic research: both MRA and DSA were
evaluated on the same patient, and compared withr Surgery. Published by Elsevier Ltd. All rights reserved.
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uation of clinical utility and patient outcomes ob-
served when performing MRA instead of DSA in
daily practice.
The purpose of our study was to prospectively
compare the diagnostic and therapeutic confidence,
the patient outcome (in terms of treatment) and costs
between MRA and DSA as the initial diagnostic imag-
ing test in patients with symptomatic arterial disease
of the leg. We performed a diagnostic trial where
the imaging was part of the treatment.Material and Methods
Patients
Between November 2004 and November 2006, we
approached all eligible patients from the department
of vascular surgery. Baseline characteristics were col-
lected for each patient with symptomatic arterial dis-
ease (ankle-brachial index of less than 0.90) and were
referred for a diagnostic imaging work-up to evaluate
the feasibility of a revascularisation procedure. Patients
had either severe disabling intermittent claudication
(Fontaine classification IIb) or critical ischemia accord-
ing to the SVS/ISCVS criteria (Fontaine classification III
or IV).14
Excluded were patients with acute ischemia and
contra-indications for MRA or DSA: Kreatinine
> 170 mmol/l, claustrophobia, metal clips in vital
organs and pacemakers.
Primary endpoints were patient satisfaction and
necessity for additional imaging. Secondary end-
points were treatment plan, types of treatment (con-
servative, angioplasty, surgery) and costs.
The study was approved by the hospital institu-
tional review board (WO 03.070) and informed con-
sent was obtained from all patients. The study was
performed according to Good Clinical Practice guide-
lines.15 Data are analyzed and reported in accordance
with the guidelines of the Consolidated Standards of
Reporting Trials.16
Study design
Patients were randomly allocated to either MRA as
diagnostic strategy, or DSA. A non-stratified com-
puter-generated randomization sequence was made.
The allocation sequence was concealed by means of
sealed opaque consecutively numbered envelopes.
Patients were enrolled by the vascular surgeons,
who were unaware of the randomization sequence.Imaging techniques
Imaging was performed on a 1.5 Tesla MR system
(Philips Gyroscan Intera T15-N release 8.1.1; Philips
Medical Systems, Best, the Netherlands). Patients
were placed in the supine position and entered into
the magnet with their feet first. The lower legs were
immobilized and placed into the surface coil.
Axial TOF views were used to plan the subsequent
image volumes for the ce-MRA scan at the three sta-
tions: aortoiliacal, femoral and crural station (TR
(ms)/TE (ms) 6.9/11.6, flip angle 50 degrees, field of
view (FOV) 430 100 mm2, matrix 256 256 mm2).
The Acquisition of the contrast enhanced images
were performed with a fast 3D spoiled gradient-
echo sequence (T1-FFE/M; TR¼ 6.0; TE¼ 1.52; flip
angle¼ 35, FOV¼ 430 mm, no flow compensation).
The standard quadrature body coil was used for sig-
nal transmission and reception. Non-enhanced 3D
data sets were obtained for each station and later sub-
tracted from the identical contrast-enhanced data sets
to increase vessel to background noise.
Images were acquired in the coronal plane and the
number of slices and imaging parameters were for all
the 3 stacks identical: 70 slices of 1.5 mm. The actually
measured partition thickness was 3 mm and later
interpolated to 1.5 mm. In-plane resolution was
0.84 0,84 1.5 mm3. The maximum total coverage
in the feet head direction was 126 cm. To ensure that
all arteries were included in the FOV, we used a 30-
mm overlap between consecutive stations. The scan
time of the individual stacks was 28.3 sec. Table move-
ment was scanner controlled and the time between 2
consecutive scans was approximately 5 seconds. For
all patients a dedicated peripheral surface coil was
used at the crural station (Synergy Body Coil, 4 ele-
ments, Philips medical system).
A paramagnetic contrast agent (0.4 ml Gd/kg
bodyweight, Gadodiamine 0.5 M [Omniscan, Ny-
comed]) was injected per patient to enhance intravas-
cular signal. The body-weight-adjusted dose was
diluted with 0.9% saline to a total standard scan
volume of 33 ml contrast medium solution. Those
patients of over 82.5 kg in whom the total amount of
the body-weight-adjusted dose exceeded 33 ml of con-
trast agent were also maximized to the standard scan
volume of 33 ml. Contrast medium was administered
as a single continuous bolus in an antecubital vein at
a rate of 1.0 ml/sec for the first 10 ml, followed by
a rate of 0.2 ml/sec for the next 20 ml of contrast. Im-
mediately after injection of contrast material, 20 ml of
normal saline was administered at a flow rate of
0.2 ml/sec to flush tubing and veins. All injectionsEur J Vasc Endovasc Surg Vol 35, May 2008
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injection system (Medrad Spectris, Pittsburgh, PA).
To minimize venous enhancement, the ce-MRA im-
ages were first obtained at the crural station, and sub-
sequently at the femoral and aortoiliacal station,
scanning a feet-to-head direction. The start of the
scan at the crural station was based on the determina-
tion of the arrival time of contrast material at the fem-
oral station of the symptomatic extremity of interest
indicated by the ordering vascular surgeon. Accord-
ing to our experience, real time detection of the bolus
arrival is too difficult to establish in the severely dis-
eased and smaller arteries of the crural station. A
3 ml undiluted contrast agent test bolus was injected
at a rate of 5 ml/sec and monitored at the femoral sta-
tion using real time bolus monitoring software (Bolus-
Trak, Philips Medical Systems). The scan delay of the
crural station was then calculated by the arrival time
at the femoral station and a standard 25 seconds
was added for all patients allowing contrast material
to reach the ankle (scan delay¼ femoral arrival
timeþ 25 seconds). After completion of the feet-to-
head scan an additional scan of the crural station
was performed supplying dynamic information.
DSA examinations were performed by experienced
interventional radiologists. Imaging was performed
on a Philips Integris 3000 digital angiography
equipment.
DSA images were obtained after standard retro-
grade femoral access of the common femoral artery
by placing a 5 French pigtail catheter below the level
of the renal arteries to image the abdominal aorta
(Cordis, Johnson-Johnson). The cathether was then
repositioned proximal to the aortic bifurcation to im-
age the pelvis, upper e and lower leg and feet. Ante-
roposterior projections were obtained on all stations
with additional 30 degrees right and left anterior-
oblique images. Non-ionic contrast was injected
through an automatic pump at varying volumes
(max. 200 ml) and rates (10e15 ml/sec) depending
on the level of interest (Iohexol, Omnipaque 300;
Nycomed-Amersham, Eindhoven, The Netherlands).Measurement of clinical utility and patients outcomes
We assessed the treatment plan during the weekly
vascular conference, where therapeutic decisions
were made in consensus. Sometimes, when indicated,
an angioplasty was performed during the DSA ses-
sion in consensus between the radiologist and the vas-
cular surgeon on call. Furthermore, when it was not
possible to make a definitive treatment plan recom-
mendations for additional imaging were measured.Eur J Vasc Endovasc Surg Vol 35, May 2008The patient confidence was measured by a Prefer-
ence Scale (PS).17 In the PS the patient is asked how
the diagnostic investigation was experienced on a 4
or 5 point scale for items like: pain during the imag-
ing, claustrophobia, noisiness, length of investigation,
inactivation due to the investigation, willingness to
undergo the imaging again. Non-responding patients
were contacted by telephone to obtain as much com-
plete data as possible.Measurement of costs
For the cost analysis we collected all relevant informa-
tion of in-hospital medical care, used by the patient
during the first 4 months. Then we calculated the
mean cost per imaging strategy per patient. The cost
of diagnostic imaging included the initial examina-
tion, all additional imaging and associated hospital
admissions, including total operative and interven-
tional costs. All costs were computed from hospital
perspective according to the costs of the different per-
formances. This cost profile included also laboratory
costs and costs of physiotherapy and overhead. Infor-
mation on costs was obtained from records of our Fi-
nancial Services Department. All costs are reported in
Euros for the year 2006.Statistical analysis
The required sample size was estimated on the basis
of the primary outcome measure, which was the pa-
tients’ preference for a certain diagnostic work up, as-
suming that kinds of treatments and treatment
outcomes were equal.17 We assumed that the differ-
ence in patient satisfaction would be 15%: 95% in
the MRA group compared to 80% in the DSA group.17
With a power of 90% and an alpha level of 5%, we
would require at least 99 patients in each group.
The results were analyzed according to the inten-
tion-to-treat principle. Continuous variables with nor-
mal distributions (expressed as means SD) were
compared with the use of an unpaired Student’s
t-tests. The c2 test was used for dichotomous and cat-
egorical outcomes and the Mann-Whitney test for
non-parametric outcomes. The relative risk (RR) was
calculated with 95% confidence intervals (95% CI).
In addition the differences adjusted for predictive
baseline characteristics were analyzed by using multi-
variate multiple logistic regression analysis. It was
assumed that the severity of the disease (Fontaine
classification), cardiac disease and diabetes mellitus
were potentially predictive for outcome.
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indicated a statistical significant difference. Calcula-
tions were performed with SPSS 14.0 for Windows
(SPSS, Chicago, Ill).Results
Patient enrollment
A total of 391 patients were assessed for eligibility
(Fig. 1). We planned to enroll 200 patients, however
97 patients were assigned to undergo MRA and 100
were assigned to undergo DSA. Three randomization
numbers were lost: in one case the envelope with
a randomization number (DSA) was lost and 2
patients were included twice (both times second ran-
domization in the DSA group). The first randomiza-
tion was included in the analysis (once MRA andAssessed for eli
(n=391) 
Randomised
(n=199)
Allocated to MRA (n=97) 
Analysed for primary endpoints,
intention to treat (n=91)
No imaging performed (n=6)
MRA not available: DSA (n=1)
Claustrophobia: DSA (n=1)
Pacemaker: DSA (n=1)
Received allocated investigation (n=89)
Did not receive allocated investigation (n=9)
Refused investigation (n=3)
Died before investigation (n=2)
Leg amputated before investigation (n=1)
Fig. 1. Flowchart of eligiblonce DSA). In one patient, included for MRA,
a DSA was performed. In the DSA group there were
more patients with diabetes and vascular disease of
the left leg (Table 1).
Nine patients did not undergo any imaging modal-
ity for various reasons. Therefore data of 188 patients
were available for the primary outcome: in the MRA
group 91 patients compared to 97 patients in the
DSA group.Clinical utility and patient outcomes
In the MRA group in 11% of patients additional diag-
nostic work up was performed compared to 10% in
the DSA group: p¼ 0.5 (Table 2). Treatment plans as
well as the ultimate treatment were not statistically
significant different in both groups of patients. In de-
tail, in 120 symptomatic right legs 78 interventionsgibility
 
Died before randomisation (n=7)
Excluded (n=67)
Renal failure: MRA (n=1)
Groin inaccessible: MRA (n=1)
Refused investigation (n=2)
Symptoms disappeared (n=1) 
Analysed for primary endpoints,
intention to treat (n=97)
No imaging performed (n=3) 
Randomisation envelope
lost (n=1)
Unjust “second”
randomisation (n=2) 
                
-     impaired renal function (21)
-     pacemaker (19)
-     claustrophobia (27)
Not meeting inclusion criteria (n=35)
Refused to participate (n=51)
Other reasons (n=32)
Received allocated investigation (n=94)
Did not receive allocated intervention (n=5):
Allocated to DSA (n=100)
e and included patients.
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Table 1. Baseline characteristics of the randomized patients*
Characteristic MRA
(n¼ 97)
DSA
(n¼ 100)
Age e yr 67 11 65 12
Male sex e no. 63 64
Previous vascular intervention right leg 24 29
Previous vascular intervention left leg 21 21
Risk factors
Diabetes mellitus 14 31
Hyperlipidemia 39 49
Tobacco use 59 65
Cardiac disease 27 35
Hypertension 51 57
Cerebrovascular disease 8 14
Creatinine (mmol/l) 77 60 75 29
Fontaine classification right leg/left leg{
No symptoms 29/43 38/28
Fontaine stage IIa 7/6 6/7
Fontaine stage IIb 37/30 29/39
Fontaine stage III 14/11 11/9
Fontaine stage IV 10/8 16/16
Ankle brachial pressure index
Right leg 0.63 0.28 0.67 0.35
Left leg 0.73 0.32 0.57 0.32
Symptomatic leg
Right leg 38 23
Left leg 33 44
Both legs 26 33
* Plus-minus values are means SD.
{ No symptoms: asymptomatic and/or Fontaine I; stage IIa: mild
symptoms: stage IIb: moderate-severe symptoms; stage III: ischemic
rest pain; stage IV: ulceration or gangrene according to the Trans-
Atlantic Inter-Society Consensus (TASC).14
Table 2. Primary outcome parameters and treatment plans of the
patients available for analysis of the primary endpoint
Outcome MRA
N¼ 91
DSA
N¼ 97
RR
(95% CI)
No additional tests necessary 81 87 1.0 (0.9 1.1)
Additional tests performed 10 10 1.1 (0.5 2.4)
MRA 0 1
DSA 2 0
Duplex 8 9
Reason additional test
Evaluation stenosis 6 5
Evaluation outflow 2 2
Evaluation aneurysm 2 3
Treatment plan right leg
No intervention{ 45 65 0.7 (0.6 0.9)*
Angioplasty 30 17
Surgery 16 15
Treatment plan left leg
No intervention{ 49 44 1.2 (0.9 1.6)*
Angioplasty 23 28
Surgery 19 25
Treatment right leg different
from plan
7 11 0.7 (0.3 1.7)
Treatment left leg different
from plan
7 6 1.2 (0.4 3.6)
Reason different treatment
Heavy calcification/no PTA or
PIER possible
3 2
More extensive surgery or
additional PTA
5 2
No reconstruction possible 0 2
Co-morbidity 2 2
No treatment or conservative
treatment
4 9
* In the MRA group there were significant more symptomatic
right legs and in the DSA group more symptomatic left legs
(Table 1).
{ No intervention means conservative treatment (¼walking
exercise) for a symptomatic leg as well as no treatment for an
asymptomatic leg.
Table 3. The preference scores for the imaging
Score* 0 1 2 3 Total
MRA (%) 46 (84) 7 (13) 2 (4) 0 (0) 55 (100)
DSA (%) 32 (57) 20 (36) 2 (4) 2 (4) 56 (100)
Total (%) 78 (70) 27 (24) 4 (4) 2 (2) 111 (100)
* Question: How did the patient experience the imaging? 0:
comfortable; 1: somewhat comfortable; 2: uncomfortable; 3: very
uncomfortable. P-value¼ 0.013 (Chi-Square test).
518 A. C. Vahl et al.were planned (65%) and in 95 of 136 symptomatic left
legs (70%). The reasons for a different treatment from
the treatment plan did not differ between the two
groups.
With adjustment for unbalanced baselines scores
and potential interaction between subgroups of pa-
tients (diabetes, cardiac disease, sex, Fontaine classifi-
cation and ankle-brachial index) we found no
statistically significant differences in outcome for
MRA compared to DSA in terms of treatment plans,
treatment and necessity for additional imaging. With
Fontaine II additional imaging was performed in 8 pa-
tients in the MRA group, compared to 7 in the DSA
group. With Fontaine III and IV these numbers are 3
patients in both groups: adjusted Odds Ratio 1.8
(95% CI 0.2e13.4).
The response for the PS list was 60% in the MRA
group compared to 58% in the DSA group.
84% of the patients in the MRA group judged the
diagnostic work up as comfortable compared to 57%
in the DSA group: p¼ 0.013 (Table 3). 75% of the pa-
tients in the MRA group compared tot 40% of the pa-
tients in the DSA group were willing to undergo the
imaging again: p¼ 0.008 (Table 4). Patients in theEur J Vasc Endovasc Surg Vol 35, May 2008MRA group experienced less pain but the imaging
was more noisiness ( p¼ 0.010) (Table 5). There were
9 complications in the MRA group (groin hematoma
after angioplasty (n¼ 3), cerebral infarction (n¼ 1),
dissection after angioplasty (n¼ 1) and death (n¼ 4:
before imaging n¼ 2 and per procedural n¼ 2) com-
pared to 6 in the DSA group (cerebral infarction
(n¼ 1), dissection after angioplasty (n¼ 1), in stent
thrombosis (n¼ 1), myocardial infarction (n¼ 1) and
death (n¼ 2).
Table 4. Willingness tot undergo the imaging again
Score* 0 1 2 3 4 Total
MRA (%) 0 (0) 2 (4) 2 (4) 10 (18) 41 (75) 55 (100)
DSA (%) 1 (2) 4 (7) 4 (7) 25 (44) 23 (40) 57 (100)
Total (%) 1 (1) 6 (5) 6 (5) 35 (31) 64 (57) 112 (100)
* Does the patient have objections to repeat the same imaging in
future? 0: absolutely not; 1: preferably not; 2: no preference; 3: only
when it is necessary; 4: absolutely yes. P¼ 0.008 (Chi-Square test).
Table 6. Outcomes and treatments during the first 4 months after
randomisation
Variable MRA
N¼ 97
DSA
N¼ 100
RR (95% CI)
Mortality 7 5 1.4 (0.5 4.4)
No imaging 6 3 2.1 (0.5 8.0)
Patients with vascular
reconstructions{
30 34 0.9 (0.6 1.4)
Surgical procedures
Aorto-iliacal bypass or
endarterectomy
8 5
Femoral endarterectomy
or cross over bypass
23 17
Femoropopliteal bypass 17 12
Distal bypass 4 6
Major amputation 6 3
Minor amputation 6 6
Other surgery* 23 32
Patients treated by
angioplasty{
39 36 1.1 (0.8 1.6)
Aortoiliac 25 20
Femoral/distal# 14 16
Patients treated
conservatively
23 30 0.8 (0.5 1.3)
* Necrosectomy, thrombectomy, revision surgery, hernia, intesti-
nal surgery.
{ One or more vascular procedures; 1 patient in the MRA group
had angioplasty in a combined session with surgery compared
with 4 patients in the DSA group.
# Percutaneous transluminale angioplasty (PTA) or percutaneous
intentional extra luminal revascularization (PIER).
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Table 6 shows the outcomes and treatment during 4
months after randomization. In 134 patients one or
more vascular interventions were performed in one
or both legs and 53 patients were treated conserva-
tively. Six more patients died during follow up:
MRA (n¼ 3); DSA (n¼ 3). Nine patients had a major
amputation: MRA (n¼ 6) compared to DSA (n¼ 3).
Within 4 months of randomization 30 patients in the
MRA group compared to 34 patients in de DSA group
underwent operative procedures (included respec-
tively 1 compared to 4 combined procedures) and 39
patients in the MRA compared to 36 patients in the
DSA group underwent angioplasty (Table 6).
The mean total in hospital costs (including imag-
ing) during the first 4 months were V 4768,- in the
MRA group compared to V 4697,- in the DSA group
(Table 7).Table 5. Baseline functional and cognitive status measurements
before and after imaging
Variable* MRA N¼ 57
Mean score
DSA N¼ 57
Mean score
p-value{
Pain Start 0.298 Start 0.667 0.016
During 0.236 During 0.628 0.000
End 0.236 End 0.577 0.002
Fear Before 0.458 Before 0.643 0.451
During 0.268 During 0.283 0.714
After 0.125 After 0.173 0.695
Claustrophobia 0.305 0.057 0.109
Noisiness 0.525 0.216 0.010
Length of imaging 0.186 0.473 0.139
Physical disturbances
after imaging: yes
N¼ 2 N¼ 9 0.081
Mental
disfunctioning: yes
N¼ 2 N¼ 4 0.624
Influence daily
activities
0.340 0.500 0.737
Perceived worth of
imaging
0.200 0.536 0.013
Willingness to
undergo same
investigation#
3.636 3.140 0.008
* Patients were asked for: no complaints (score 0), mild (score 1),
moderate (score 3) and severe complaints (score 4). In this table only
the numbers of patients with ‘‘no complaints’’ are mentioned.
{ Chi-Square test.
# 5 point scale: 0: absolutely not; 1: preferably not; 2: no prefer-
ence; 3: only when it is necessary; 4: absolutely yes.Discussion
A randomized controlled diagnostic trial was per-
formed to evaluate the clinical utility, patient out-
comes and costs of 2 diagnostic strategies: MRA
compared to the reference standard DSA. Patients ex-
perienced that MRA was more comfortable and less
painful. There was no statistically significant differ-
ence in ability to make a treatment plan, need for ad-
ditional diagnostic work up, kinds and amount of
invasive procedures which were performed during 4
month of follow up. The results suggest that MRA
might replace DSA as the initial diagnostic modalityTable 7. Total costs during 4 months after randomization
Estimated total
costs (V)
MRA
N¼ 97
DSA
N¼ 100
Mean
difference
95% CI of
mean diff.
Mean total costs 4768 4697 71 (L1331, 1472)
Admission 2200 2001 199 (765 4, 1163)
Day care 79 183 103 (146, 61)
Radiology 1135 1355 220 (519, 79)
Laboratory 24 28 4 (12, 4)
Operation costs 1001 939 61 (394, 517)
Intensive care 215 220 5 (410, 400)
Microbiological
cultures
30 24 6 (11, 23)
Pathology 3 4 1 (6, 4)
Physiotherapy 4 4 0 (3, 3)
ECG etc. 6 9 3 (8, 1)
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520 A. C. Vahl et al.in the diagnostic work up in patients with peripheral
arterial disease.
From meta-analysis of 34 studies in 1090 patients it
was concluded that MRA is highly accurate for the
assessment of the entire lower extremity for arterial
disease, compared to the reference standard: DSA.2
Three dimensional CE-MRA proved to be superior
to 2-DMRAwith an estimated point of equal sensitiv-
ity and specificity of 94%. More recent studies, with
ongoing experience, the MRA performed even better
with a diagnostic accuracy of more than 95%.18,19,
However, technical problems with MRA can occur
in 14% of cases, of whom venous over projection in
the crural segment is the most disturbing. This may
lead in 6% of the patients to additional imaging.20
Our patients judged the MRA as more comfortable
compared to the DSA. Likewise, in a study with 30 pa-
tients were both MRA and DSA were performed in
each case, patients experienced the MRA as more
comfortable.17 Patients who had both diagnostic mo-
dalities experienced limitations on daily activities
and physical function. This was not the case in our pa-
tients. Our patients had more pain during the DSA.
This is in contrast with a study in which the patients
scored the same pain category during MRA and
DSA.17 Our MRA patients were willing to undergo
the procedure again. This is in line with the literature
where both diagnostic modalities were performed in
the same patients. Patients were willing to pay
2.12% of annual income to avoid MRA compared to
7.41% for DSA. The differences of both outcomes
were statistically significant.17
Our study proved that for both imaging tech-
niques the necessity for additional imaging to make
a treatment plan is not statistically significant differ-
ent. In 90% of the patients the initial imaging is con-
clusive to make a treatment plan. In another study
additional DSA, after MRA, was judged to be neces-
sary in 33% of the cases.21 In another diagnostic trial
it was necessary to perform additional imaging in
17% of the cases after an initial MRA imaging during
a 6 months follow up.22 Additional imaging in our
study was less frequent. Mostly, we had to perform
additional DUS in order to evaluate a possible steno-
sis, suggested on MRA as well as on DSA. Venous
contamination can be a problem in up to 5% of
the cases and was minimalized by adapting the
protocol.11,20 In this way MRA proved to be able of
identifying more patent crural vessels, compared
to DSA.23
MRA has some limitations. There is a contra-
indication in patients with some form of metal (e.g.
pacemaker) in their body. Also intra arterial stents
cause artifacts. This can be the reason for additionalEur J Vasc Endovasc Surg Vol 35, May 2008imaging. Claustrophobia can be a contra-indication
and is reported in up to 12% of the cases.21 The alter-
native can be another minimal invasive technique
like the CTA. The interobserver agreement in CTA is
slightly less than for MRA: Kappa 0.85 compared to
0.90 for all segments.22 Calcifications, especially in
the crural segments, can cause problems with interpre-
tation. In a diagnostic trial it was concluded that the
physicians confidence in making a correct therapeutic
choice was significantly lower in CTA compared to
DSA.24 However, considering the equal quality of
live in both treatment arms and that CTA as initial
diagnostic imaging was significantly cheaper, it was
concluded that CTA provides sufficient information
for therapeutic decision making. In another trial CTA
and MRA proved to be equal, where only the mean
costs of diagnostic imaging was slightly higher.22
Striking is the fact that, despite the indication for
the diagnostic imaging not all patients had invasive
treatment. The main reason is that the balance be-
tween the vascular complaints and the possible treat-
ment options, considering the patients condition and
co-morbidity, was unfavorable in some cases.21 Our
results are in line with other studies were the percent-
ages vary between 56% and 71%.21,22,24
There were limitations in our study. The evaluation
of the imaging, making the treatment plan and the
treatment were not blinded. Patients were known by
the physicians and treatment plans were in accordance
with patient’s condition and wishes. There were
differences in baseline characteristics. Despite these
differences, the conclusion of our study did not alter
after adjustment for these variables. Cost calculations
are from hospital perspective and not from social per-
spective. The treatments were not different, so we don’t
expect differences in these patients of whom the most
are retired from active participation in work process.
In conclusion, an adequate treatment plan can be
made with MRA in patients with peripheral arterial
disease of the leg. This diagnostic modality is experi-
enced as more comfortable and less painful compared
to DSA, with a trend of a better quality of life 4 months
after randomization. Total treatment costs and clinical
outcomes of both modalities are comparable.References
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